Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide with many patients progressing to advanced kidney disease despite maximization of supportive measures, including optimization of reninangiotensin system blockade. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a class of drug originally intended for decreasing blood glucose in diabetes, have been shown to reduce the risk of kidney disease progression in both diabetic and non-diabetic kidney disease, including IgAN.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: